Wall Avenue is experiencing a interval of uncertainty, buying and selling totally on the fixed updates and headlines about Iran and the Strait of Hormuz. The bulls are exhibiting they’re prepared and prepared to carry their floor primarily based on the prospects of de-escalation within the rapid future.
If the Center East battle is resolved sooner somewhat than later, the market seems to be in a great place because the earnings outlook retains getting higher. That mentioned, traders seeking to purchase shares ought to contemplate firms which have already confirmed they can keep far above the Iran-based promoting.
The momentum shares this display places in your radar haven’t solely climbed to commerce close to their highs amid March market turmoil, however they’ve additionally skilled sturdy upward earnings revisions that earn them Zacks Rank #1 (Sturdy Buys) proper now.
Let’s dive into how traders can discover one of the best “Sturdy Purchase” momentum shares so as to add to their portfolios heading into April and all through 2026.
How one can Discover the High Momentum Shares to Purchase
The display we’re wanting into right this moment comes loaded with the Analysis Wizard. The display helps traders dig via all the Zacks Rank #1 (Sturdy Purchase) shares, of which there are over 200 at any given time, to search out a number of the prime momentum names.
The display narrows down the record of Zacks Rank #1 (Sturdy Purchase) stocksto these with upward value momentum which are additionally buying and selling inside 20% of their 52-week highs. The display then makes use of the PEG ratio and the Value to Gross sales ratio to assist be certain traders are getting worth as effectively. The display then makes your life a little bit simpler and narrows it down to simply seven inventory picks.
The display fundamentals are listed under…
· Zacks Rank = #1 (Sturdy Purchase)
· Present Value/52-week Excessive >= 0.8
· PEG Ratio: P/E F(1)/EPS Development <= 1
· Value/Gross sales <= 3
· Proportion Change Value -12 Weeks = High # 7
This technique comes loaded with the Analysis Wizard and it’s known as bt_sow_momentum_method1 It may be discovered within the SoW (Display screen of the Week) folder.
The display is easy, but highly effective. Right here is one of the seven shares that made it via this week’s display…
Purchase Hovering High-Ranked Medical Inventory PAHC for Worth, Development and Breakout Potential
Phibro Animal Well being Company PAHC is an animal well being and mineral vitamin firm that posted huge gross sales and earnings progress final 12 months. The inventory has soared over 330% prior to now two years, together with a 46% YTD cost to new all-time highs, which helped it escape above its earlier 2018 peaks.
Picture Supply: Zacks Funding Analysis
PAHC works with livestock producers, farmers, veterinarians, and shoppers. Phibro Animal Well being sells roughly 780 product strains in over 80 international locations to almost 4,000 prospects to assist stop, management and deal with ailments, and assist vitamin. Phibro Animal Well being’s choices are designed for meals and companion animals, together with poultry, swine, beef and dairy cattle, aquaculture, and canine.
The animal well being agency’s earnings estimates have surged since its final report, extending a formidable run of upward revisions. PAHC’s FY26 estimate has jumped 10% over the previous few months, with its FY27 outlook 12% larger, serving to it land its Zacks Rank #1 (Sturdy Purchase).
Phibro Animal Well being has grown its income steadily during the last decade, except for a Covid-related dip, together with 27% gross sales enlargement in fiscal 2025 (ended on June 30).
Wanting forward, it’s projected to observe that up with 15% income progress in FY26 and 4% in FY27 to succeed in $1.54 billion. It’s also anticipated to broaden its adjusted earnings by 45% in FY26 and eight% subsequent 12 months, following 75% YoY enlargement in FY25.
Picture Supply: Zacks Funding Analysis
PAHC inventory held its floor at some key technical ranges. Plus, it trades at a 15% low cost to its Medical sector, at its personal 10-year median, and a 38% low cost to its highs at 16.7X ahead 12-month earnings.
That’s removed from a lofty valuation and showcases that PAHC inventory may have lots extra room to run given its spectacular progress outlook.
Get the remainder of the shares on this record and begin searching for the latest firms that match these standards. It is simple to do. And it may make it easier to discover your subsequent large winner. Begin screening for these firms right this moment with a free trial to the Analysis Wizard. You are able to do it.
Click on right here to enroll in a free trial to the Analysis Wizard right this moment.
Need extra articles from this creator? Scroll as much as the highest of this text and click on the FOLLOW AUTHOR button to get an electronic mail every time a brand new article is revealed.
Disclosure: Officers, administrators and/or workers of Zacks Funding Analysis could personal or have bought quick securities and/or maintain lengthy and/or quick positions in choices which are talked about on this materials. An affiliated funding advisory agency could personal or have bought quick securities and/or maintain lengthy and/or quick positions in choices which are talked about on this materials.
Disclosure: Efficiency data for Zacks’ portfolios and methods can be found at: www.zacks.com/performance_disclosure
See As we speak’s Picks from Zacks’ High Screens – Free
You are invited to entry our assortment {of professional} inventory screens at no cost contained in the Analysis Wizard.
These screens have crushed the market since 2000. For instance, Small-Cap Development averages +42.9% annual positive factors, Filtered Zacks Rank5 returns +45.4%, and Huge Cash Zacks generates +51.8%.
Strive these screens for your self with a FREE Analysis Wizard trial. Or create your individual methods to suit your distinctive buying and selling model. No bank card wanted, no price or obligation.
Strive it for two weeks free >>
Phibro Animal Well being Company (PAHC) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
